

Howard H Feldman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6825664/publications.pdf>

Version: 2024-02-01

149
papers

50,267
citations

15504

65
h-index

8866

145
g-index

164
all docs

164
docs citations

164
times ranked

38040
citing authors

#	ARTICLE	IF	CITATIONS
1	The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 270-279.	0.8	7,498
2	Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. <i>Science</i> , 2006, 314, 130-133.	12.6	5,422
3	Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. <i>Neuron</i> , 2011, 72, 245-256.	8.1	4,176
4	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. <i>Lancet Neurology</i> , The, 2007, 6, 734-746.	10.2	3,755
5	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.1	2,805
6	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , The, 2014, 13, 614-629.	10.2	2,657
7	Mild cognitive impairment. <i>Lancet</i> , The, 2006, 367, 1262-1270.	13.7	2,401
8	Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. <i>Nature</i> , 2006, 442, 916-919.	27.8	1,816
9	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.8	1,318
10	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , The, 2016, 15, 455-532.	10.2	1,242
11	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016, 87, 539-547.	1.1	1,216
12	Nonpharmacological Therapies in Alzheimer's Disease: A Systematic Review of Efficacy. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 161-178.	1.5	720
13	Treatment of Alzheimer's disease; current status and new perspectives. <i>Lancet Neurology</i> , The, 2003, 2, 539-547.	10.2	664
14	Dementia with Lewy bodies. <i>Lancet Neurology</i> , The, 2004, 3, 19-28.	10.2	645
15	Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. , 2011, 7, 367-385.		531
16	Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. <i>Human Molecular Genetics</i> , 2006, 15, 2988-3001.	2.9	529
17	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. <i>Nature Genetics</i> , 2010, 42, 234-239.	21.4	479
18	Sortilin-Mediated Endocytosis Determines Levels of the Frontotemporal Dementia Protein, Progranulin. <i>Neuron</i> , 2010, 68, 654-667.	8.1	465

#	ARTICLE	IF	CITATIONS
19	Candidate Single-Nucleotide Polymorphisms From a Genomewide Association Study of Alzheimer Disease. <i>Archives of Neurology</i> , 2008, 65, 45-53.	4.5	443
20	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology</i> , The, 2021, 20, 484-496.	10.2	396
21	Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. <i>Neurobiology of Aging</i> , 2012, 33, 1203-1214.e2.	3.1	346
22	Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. <i>Lancet Neurology</i> , The, 2007, 6, 501-512.	10.2	314
23	Safety and Tolerability of the Î³-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 1430.	4.5	314
24	Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. <i>Lancet</i> , The, 2016, 388, 2873-2884.	13.7	299
25	Cholesterol in Alzheimer's disease. <i>Lancet Neurology</i> , The, 2005, 4, 841-852.	10.2	292
26	The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. <i>Brain</i> , 2006, 129, 3081-3090.	7.6	291
27	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. <i>Human Molecular Genetics</i> , 2008, 17, 3631-3642.	2.9	271
28	Worldwide FINGERS Network: A global approach to risk reduction and prevention of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 1078-1094.	0.8	257
29	The Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease. <i>Focus (American Psychiatric Publishing)</i> , 2013, 11, 96-106.	0.8	241
30	Emerging Therapies for Vascular Dementia and Vascular Cognitive Impairment. <i>Stroke</i> , 2004, 35, 1010-1017.	2.0	212
31	Efficacy of Donepezil on Behavioral Symptoms in Patients With Moderate to Severe Alzheimer's Disease. <i>International Psychogeriatrics</i> , 2002, 14, 389-404.	1.0	211
32	Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. <i>Brain</i> , 2012, 135, 709-722.	7.6	201
33	Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C>T (Arg493X) mutation: an international initiative. <i>Lancet Neurology</i> , The, 2007, 6, 857-868.	10.2	199
34	Diagnosis and treatment of dementia: 2. Diagnosis. <i>Cmaj</i> , 2008, 178, 825-836.	2.0	196
35	Efficacy of Donepezil on Maintenance of Activities of Daily Living in Patients with Moderate to Severe Alzheimer's Disease and the Effect on Caregiver Burden. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 737-744.	2.6	189
36	Targeting Prodromal Alzheimer Disease With Avagacestat. <i>JAMA Neurology</i> , 2015, 72, 1324.	9.0	179

#	ARTICLE	IF	CITATIONS
37	Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 196-203.	1.9	170
38	The Spectrum of Mutations in Progranulin. <i>Archives of Neurology</i> , 2010, 67, 161-70.	4.5	166
39	Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. <i>Nature Medicine</i> , 1996, 2, 1230-1235.	30.7	165
40	The rights of precision drug development for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 76.	6.2	148
41	Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2006, 20, 732-755.	4.0	145
42	Apolipoprotein E ϵ 4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. <i>Cmaj</i> , 2004, 171, 863-867.	2.0	144
43	Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. <i>Depression and Anxiety</i> , 2010, 27, 417-425.	4.1	144
44	Synaptic dysfunction in progranulin-deficient mice. <i>Neurobiology of Disease</i> , 2012, 45, 711-722.	4.4	144
45	Ubiquitin Immunohistochemistry Suggests Classic Motor Neuron Disease, Motor Neuron Disease With Dementia, and Frontotemporal Dementia of the Motor Neuron Disease Type Represent a Clinicopathologic Spectrum. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 730-739.	1.7	143
46	Potential for misclassification of mild cognitive impairment: A study of memory scores on the Wechsler Memory Scale-III in healthy older adults. <i>Journal of the International Neuropsychological Society</i> , 2008, 14, 463-478.	1.8	140
47	Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. <i>Alzheimer's Research and Therapy</i> , 2013, 5, S2.	6.2	129
48	Epidemiology and genetics of frontotemporal dementia/Pick's disease. <i>Annals of Neurology</i> , 2003, 54, S29-S31.	5.3	120
49	Neuropsychological testing and assessment for dementia. <i>Alzheimer's and Dementia</i> , 2007, 3, 299-317.	0.8	112
50	Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration. <i>Archives of Neurology</i> , 2011, 68, 488.	4.5	108
51	Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 559-569.	2.7	105
52	A family with tau-negative frontotemporal dementia and neuronal intranuclear inclusions linked to chromosome 17. <i>Brain</i> , 2006, 129, 853-867.	7.6	102
53	Can we prevent Alzheimer's disease? Secondary prevention trials in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2013, 9, 123.	0.8	100
54	Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019, 137, 209-226.	7.7	100

#	ARTICLE	IF	CITATIONS
55	Therapeutic potential of statins in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2009, 283, 230-234.	0.6	99
56	Cognition, Function, and Caregiving Time Patterns in Patients With Mild-to-Moderate Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2005, 19, 29-36.	1.3	94
57	Clinical phenotypes of Cerebral Amyloid Angiopathy. <i>Journal of the Neurological Sciences</i> , 2007, 257, 23-30.	0.6	93
58	Mild Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 645-655.	1.2	88
59	The Consortium to Investigate Vascular Impairment of Cognition: Methods and First Findings. <i>Canadian Journal of Neurological Sciences</i> , 2003, 30, 237-243.	0.5	86
60	Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1056-1063.	1.9	81
61	rs5848 polymorphism and serum progranulin level. <i>Journal of the Neurological Sciences</i> , 2011, 300, 28-32.	0.6	77
62	Periventricular hyperintensities are associated with elevated cerebral amyloid. <i>Neurology</i> , 2016, 86, 535-543.	1.1	75
63	Differentiating the frontal variant of Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 732-738.	2.7	73
64	Superficial Siderosis. <i>Stroke</i> , 2008, 39, 2894-2897.	2.0	72
65	Activities of Daily Living in Moderate-to-Severe Alzheimer Disease: An Analysis of the Treatment Effects of Memantine in Patients Receiving Stable Donepezil Treatment. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, 263-268.	1.3	67
66	Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 479-488.	2.7	64
67	Prevention trials in Alzheimer's disease: An EU-US task force report. <i>Progress in Neurobiology</i> , 2011, 95, 594-600.	5.7	62
68	Dependence as a unifying construct in defining Alzheimer's disease severity. <i>Alzheimer's and Dementia</i> , 2010, 6, 482-493.	0.8	61
69	Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. <i>Neurology</i> , 2013, 81, 1322-1331.	1.1	60
70	Pharmacodynamics of Selective Inhibition of β -Secretase by Avagacestat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 686-695.	2.5	59
71	Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development. <i>Alzheimer's and Dementia</i> , 2013, 9, 176-188.	0.8	58
72	The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics. <i>Alzheimer's and Dementia</i> , 2008, 4, 145-153.	0.8	56

#	ARTICLE	IF	CITATIONS
73	The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 499-511.	0.5	56
74	Outcomes of Cognitively Impaired Not Demented at 2 Years in the Canadian Cohort Study of Cognitive Impairment and Related Dementias. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 413-420.	1.5	53
75	Synergistic effect of apolipoprotein E ϵ 4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 289-298.	1.5	49
76	Minimizing Misdiagnosis: Psychometric Criteria for Possible or Probable Memory Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 439-450.	1.5	49
77	The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal) Tj ETQq1 1 0.784314 rgBT / Overlock 10	0.8	48
78	A Randomized, Controlled Trial of Linopirdine in the Treatment of Alzheimer's Disease. <i>Canadian Journal of Neurological Sciences</i> , 1997, 24, 140-145.	0.5	47
79	The relationship between extramotor ubiquitin-immunoreactive neuronal inclusions and dementia in motor neuron disease. <i>Acta Neuropathologica</i> , 2003, 105, 98-102.	7.7	47
80	Evaluation of late-onset Alzheimer disease genetic susceptibility risks in a Canadian population. <i>Neurobiology of Aging</i> , 2014, 35, 936.e5-936.e12.	3.1	47
81	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. <i>Alzheimer's and Dementia</i> , 2020, 16, 131-143.	0.8	45
82	Effectiveness of Donepezil in Reducing Clinical Worsening in Patients with Mild-to-Moderate Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 244-251.	1.5	44
83	Canadian Guidelines for the Development of Antidementia Therapies: a Conceptual Summary. <i>Canadian Journal of Neurological Sciences</i> , 1995, 22, 62-72.	0.5	42
84	Effect of diesel exhaust inhalation on blood markers of inflammation and neurotoxicity: a controlled, blinded crossover study. <i>Inhalation Toxicology</i> , 2016, 28, 145-153.	1.6	39
85	A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. <i>Nature Communications</i> , 2021, 12, 7065.	12.8	38
86	Neuronal intranuclear inclusions distinguish familial FTD-MND type from sporadic cases. <i>Acta Neuropathologica</i> , 2003, 105, 543-548.	7.7	37
87	Disease progression in vascular cognitive impairment: Cognitive, functional and behavioural outcomes in the Consortium to Investigate Vascular Impairment of Cognition (CIVIC) cohort study. <i>Journal of the Neurological Sciences</i> , 2007, 252, 106-112.	0.6	36
88	An exploration of cognitive subgroups in Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2010, 16, 233-243.	1.8	35
89	Clinical and radiographic subtypes of vascular cognitive impairment in a clinic-based cohort study. <i>Journal of the Neurological Sciences</i> , 2006, 240, 7-14.	0.6	33
90	Sleep and its regulation: An emerging pathogenic and treatment frontier in Alzheimer's disease. <i>Progress in Neurobiology</i> , 2021, 197, 101902.	5.7	33

#	ARTICLE	IF	CITATIONS
91	Alzheimer's disease research and development: a call for a new research roadmap. <i>Annals of the New York Academy of Sciences</i> , 2014, 1313, 1-16.	3.8	31
92	Safety and Efficacy of Edonepic Maleate for Patients With Mild to Moderate Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 1330.	9.0	29
93	Cognitive heterogeneity in probable Alzheimer disease. <i>Neurology</i> , 2019, 93, e778-e790.	1.1	27
94	What are the Treatment Options for Patients with Severe Alzheimer's Disease?. <i>CNS Drugs</i> , 2004, 18, 575-583.	5.9	26
95	Transition from Cognitively Impaired Not Demented to Alzheimer's Disease: An Analysis of Changes in Functional Abilities in a Dementia Clinic Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 483-490.	1.5	26
96	Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study. <i>Journal of the Neurological Sciences</i> , 2010, 288, 142-146.	0.6	26
97	A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. <i>Progress in Neurobiology</i> , 2013, 110, 114-123.	5.7	26
98	Gray matter changes in asymptomatic C9orf72 and GRN mutation carriers. <i>NeuroImage: Clinical</i> , 2018, 18, 591-598.	2.7	26
99	Fatal Familial Insomnia. <i>Archives of Neurology</i> , 2004, 61, 122.	4.5	25
100	Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned?. <i>Alzheimer's and Dementia</i> , 2006, 2, 220-233.	0.8	25
101	Neuropsychiatric Symptom Clusters and Functional Disability in Cognitively-Impaired-Not-Demented Individuals. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 136-144.	1.2	25
102	Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY). <i>Alzheimer's Research and Therapy</i> , 2018, 10, 102.	6.2	24
103	Delayed daily activity and reduced NREM slow-wave power in the APPswe/PS1dE9 mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 78, 74-86.	3.1	24
104	Extrapyramidal features in patients with motor neuron disease and dementia; a clinicopathological correlative study. <i>Acta Neuropathologica</i> , 2004, 107, 336-340.	7.7	23
105	Neuronal Intranuclear Inclusions Distinguish Familial FTD-MND Type from Sporadic Cases. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 333-336.	1.5	22
106	Revised research diagnostic criteria for Alzheimer's disease. <i>Lancet Neurology</i> , The, 2008, 7, 668-670.	10.2	21
107	Pharmacological treatment in moderate-to-severe Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2575-2582.	1.8	21
108	Rates of Cognitive Change in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 357-364.	1.3	21

#	ARTICLE	IF	CITATIONS
109	Early Neuropsychological Characteristics of Progranulin Mutation Carriers. <i>Journal of the International Neuropsychological Society</i> , 2014, 20, 694-703.	1.8	21
110	Therapeutic trial design for frontotemporal dementia and related disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 412-423.	1.9	21
111	Clinical Presentation of Prodromal Frontotemporal Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2008, 22, 456-467.	1.9	20
112	Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach. <i>Gender Medicine</i> , 2009, 6, 345-355.	1.4	20
113	Premature termination codon readthrough upregulates progranulin expression and improves lysosomal function in preclinical models of GRN deficiency. <i>Molecular Neurodegeneration</i> , 2020, 15, 21.	10.8	19
114	Cognitive Impairment No Dementia – Neuropsychological and Neuroimaging Characterization of an Amnesic Subgroup. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 238-247.	1.5	18
115	The 2002 NIMH Provisional Diagnostic Criteria for Depression of Alzheimer's Disease (PDC-dAD): Gauging their Validity over a Decade Later. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 449-462.	2.6	18
116	PROGRESS IN CLINICAL NEUROSCIENCES: Canadian Guidelines for the Development of Antidementia Therapies: A Conceptual Summary. <i>Canadian Journal of Neurological Sciences</i> , 2006, 33, 6-26.	0.5	17
117	Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1907.	2.4	15
118	Global issues in drug development for Alzheimer's disease. , 2011, 7, 197-207.		14
119	Value-Generating Exploratory Trials in Neurodegenerative Dementias. <i>Neurology</i> , 2021, 96, 944-954.	1.1	14
120	Neuropsychological Subgroups of Cognitively-Impaired-Not-Demented (CIND) Individuals: Delineation, Reliability, and Predictive Validity. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2005, 27, 164-188.	1.3	13
121	Primary Prevention and Delay of Onset of AD/Dementia. <i>Canadian Journal of Neurological Sciences</i> , 2007, 34, S84-S89.	0.5	13
122	Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 707-713.	2.6	12
123	Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12071.	3.7	12
124	The Canadian dementia challenge: Ensuring optimal care and services for those at risk or with dementia throughout the country. <i>Canadian Journal of Public Health</i> , 2017, 108, e95-e97.	2.3	11
125	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease. <i>Nature Communications</i> , 2022, 13, 1495.	12.8	11
126	Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2022, 79, 565.	9.0	11

#	ARTICLE	IF	CITATIONS
127	Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial. <i>Alzheimer's and Dementia</i> , 2018, 14, 1397-1405.	0.8	10
128	Neuropsychological Characterization of Cognitively-Impaired-Not-Demented (CIND) Individuals: Clinical Comparison Data. <i>Clinical Neuropsychologist</i> , 2004, 18, 208-228.	2.3	8
129	Atlas of Alzheimer's Disease. , 0, , .		7
130	New lexicon and criteria for the diagnosis of Alzheimer's disease – Authors' reply. <i>Lancet Neurology</i> , The, 2011, 10, 300-301.	10.2	7
131	Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease. <i>BMC Neurology</i> , 2006, 6, 32.	1.8	6
132	Assessing the validity of deriving clinical dementia rating (CDR) global scores from independently-obtained functional rating scale (FRS) scores in vascular dementia with and without Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 1174-1176.	2.7	6
133	Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab. <i>Canadian Geriatrics Journal</i> , 2021, 24, 373-378.	1.2	6
134	A randomized clinical trial to evaluate home-based assessment of people over 75 years old. <i>Alzheimer's and Dementia</i> , 2019, 15, 615-624.	0.8	5
135	Predicting response to acetylcholinesterase inhibitor treatment in Alzheimer disease: has the time come?. <i>Nature Reviews Neurology</i> , 2009, 5, 128-129.	10.1	4
136	Neurobehavioral characterization of adult-onset Alexander disease. <i>Neurology: Clinical Practice</i> , 2017, 7, 425-429.	1.6	4
137	16-Year Survival of the Canadian Collaborative Cohort of Related Dementias. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 367-374.	0.5	3
138	Committee on High-Quality Alzheimer's Disease Studies (CHADS) consensus report. <i>Alzheimer's and Dementia</i> , 2022, 18, 1109-1118.	0.8	3
139	Applying the Alzheimer Disease ATN Diagnostic Framework in Atypical Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2020, 34, 357-359.	1.3	3
140	Impact of potential modifications to Alzheimer's disease clinical trials in response to disruption by COVID-19: a simulation study. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 201.	6.2	3
141	Early Identification of Alzheimer's Disease: What Have we Learned from Mild Cognitive Impairment?. <i>CNS Spectrums</i> , 2008, 13, 4-7.	1.2	2
142	Output of the working group on magnetic resonance imaging abnormalities and treatment with amyloid-modifying agents. <i>Alzheimer's and Dementia</i> , 2011, 7, 365-366.	0.8	2
143	Drug Treatment: Cholinesterase Inhibitors. , 2006, , 131-149.		1
144	Canadian Guidelines for the Development of Antidementia Therapies: 2nd Canadian Conference on Antidementia Drug Guidelines. <i>Canadian Journal of Neurological Sciences</i> , 2007, 34, i-S2.	0.5	1

#	ARTICLE	IF	CITATIONS
145	F5-03-02: Perspective from the clinical research and manufacturing communities. , 2013, 9, P826-P826.		0
146	IC-P-108: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION. , 2014, 10, P60-P61.		0
147	P4-038: CREATION OF THE CANADIAN CONSORTIUM FOR NEURODEGENERATION IN AGING. , 2014, 10, P796-P796.		0
148	P2-202: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION. , 2014, 10, P546-P547.		0
149	F5â€03â€02: Biomarkers are Useful in Tertiary Care Clinical Decisionâ€Making. Alzheimer's and Dementia, 2016, 12, P370.	0.8	0